Skip to Main Content

Paper Details

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Blood
19
2022
-, B-cell receptor, BCR, BL, BL cell, Burkitt lymphoma, Cas9, SHMT, SHMT2, SHMT2i, TCF3, factor TCF3, formate, glycine, lymphoma, mTOR, master, methotrexate, one-carbon, patients, serine, serine hydroxymethyltransferase 2, transcriptional regulators
Author NameAffiliation
Michele CeribelliDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health
Yana PikmanDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Henning UrlaubMax Planck Institute for Biophysical Chemistry
Henning UrlaubGeorg August University
Joshua D RabinowitzLewis-Sigler Institute for Integrative Genomics.
Joshua D Rabinowitz
Craig J ThomasDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health
Craig J ThomasNational Cancer Institute, National Institutes of Health
Louis M StaudtNational Cancer Institute, National Institutes of Health
Louis M StaudtNational Cancer Institute, National Institutes of Health
  • 1 - 12

Datasets

Release 1.2